| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥107.7B | ¥100.4B | +7.3% |
| Operating Income | ¥3.4B | ¥3.2B | +7.7% |
| Ordinary Income | ¥4.9B | ¥3.6B | +34.4% |
| Net Income | ¥3.3B | ¥2.7B | +23.8% |
| ROE | 3.3% | 2.8% | - |
FY2025 results: Revenue 107.7B yen (YoY +7.3%), Operating Income 3.4B yen (+7.7%), Ordinary Income 4.9B yen (+34.4%), Net Income 3.3B yen (+23.8%). The company operates as a single segment with domestic sales accounting for approximately 86% of total revenue (92.6B yen domestic, 15.1B yen overseas). Revenue growth was driven by steady order intake in the domestic market. Operating margin remained at 3.2%, showing minimal improvement YoY, while the substantial 34.4% increase in ordinary income was primarily attributable to non-operating gains including dividend income of 0.9B yen and gains on sale of securities of 0.7B yen. Operating cash flow of 6.0B yen represented 1.77x net income, confirming strong cash generation quality. Free cash flow of 6.4B yen supported shareholder returns including dividends of 50.0 yen per share and share buybacks of 0.9B yen. The equity ratio of 78.6% and current ratio of 523.3% indicate robust financial health, though profitability metrics warrant attention with ROE at 3.3% and operating margin at 3.2%.
Revenue increased 7.3B yen YoY to 107.7B yen, driven primarily by domestic market growth with geographic breakdown showing Japan at 92.6B yen and overseas at 15.1B yen. The single-segment business structure precludes detailed segment-level analysis, though supplementary notes indicate the company operates in a single product/service category with over 90% of sales in that category. Cost of sales increased to 70.6B yen, maintaining a gross profit margin of 34.4% (37.0B yen), relatively stable from prior period. SG&A expenses rose to 33.6B yen (31.2% of revenue), with personnel costs of 10.1B yen and R&D expense of 1.0B yen (0.9% of revenue). The modest increase in operating income from 3.2B yen to 3.4B yen (+0.2B yen) reflects revenue growth offset by SG&A increases.
The significant gap between operating income (3.4B yen) and ordinary income (4.9B yen) of 1.5B yen was driven by non-operating gains. Non-operating income totaled 1.6B yen, comprising dividend income of 0.9B yen, interest income of 0.1B yen, interest on securities of 0.1B yen, foreign exchange gains of 0.1B yen, and other income of 0.2B yen. Non-operating expenses were minimal at 0.1B yen. Extraordinary items included gain on sale of securities of 0.7B yen offset by impairment loss of 0.5B yen and valuation loss on securities of 0.5B yen, resulting in net extraordinary impact near neutral. The progression from ordinary income (4.9B yen) to profit before tax (5.0B yen) to net income (3.3B yen) reflects income tax expense of 1.7B yen representing an effective tax rate of 34%.
This represents a revenue up, profit up pattern with revenue growth of 7.3% accompanied by operating income growth of 7.7%. However, the operating profit growth was modest in absolute terms (+0.2B yen) while ordinary income benefited significantly from non-operating gains, indicating that core business profitability improvement remains limited.
[Profitability] ROE of 3.3% remains low, indicating substantial room for improvement in capital efficiency. Operating margin of 3.2% is stable YoY but below optimal levels for sustainable profitability. Gross profit margin of 34.4% demonstrates acceptable pricing power, while SG&A ratio of 31.2% limits operating leverage. R&D intensity of 0.9% suggests moderate investment in product development. [Cash Quality] Cash and deposits of 27.5B yen plus short-term investment securities of 2.0B yen provide strong liquidity coverage. Operating cash flow of 6.0B yen exceeded net income by 1.77x, confirming high-quality earnings conversion. Free cash flow of 6.4B yen demonstrates robust cash generation capability. [Investment Efficiency] Asset turnover of 0.85 indicates moderate efficiency in asset utilization. Days sales outstanding of approximately 104 days reflects extended receivables collection cycles. Investment securities holdings of 38.1B yen represent significant financial assets relative to total assets of 126.6B yen. [Financial Health] Equity ratio of 78.6% indicates conservative capitalization with minimal financial leverage. Current ratio of 523.3% provides ample short-term liquidity cushion. Interest-bearing debt of only 0.2B yen and debt-to-equity ratio of 0.27 reflect minimal leverage. Net defined benefit liability of 6.5B yen and deferred tax liabilities of 5.2B yen represent principal non-current obligations.
Operating cash flow of 6.0B yen represents 1.77x net income of 3.3B yen, confirming strong cash-backed earnings quality. Operating cash flow before working capital changes totaled 5.5B yen, with working capital movements including inventory increase of 0.5B yen, receivables increase of 0.8B yen, and payables increase of 1.2B yen. Interest and dividends received contributed 1.0B yen to operating activities, while income taxes paid amounted to 0.6B yen. Investing cash flow of 0.4B yen comprised primarily capital expenditures of 2.3B yen, indicating continued investment in fixed assets exceeding depreciation of 1.7B yen by a capex-to-depreciation ratio of 1.37x. Financing cash flow of negative 2.8B yen reflected shareholder returns through share repurchases of 0.9B yen and dividend payments. Free cash flow of 6.4B yen (operating CF plus investing CF) provided sufficient coverage for total shareholder distributions at 2.11x, though the high payout warrants monitoring given projected earnings decline in guidance.
Ordinary income of 4.9B yen versus operating income of 3.4B yen reflects net non-operating contribution of approximately 1.5B yen, representing 1.4% of revenue. This comprises primarily dividend income of 0.9B yen and interest/securities income totaling 0.2B yen as recurring financial income, alongside foreign exchange gains of 0.1B yen subject to volatility. Non-recurring factors include extraordinary gain on sale of securities of 0.7B yen offset by impairment loss of 0.5B yen and valuation loss on securities of 0.5B yen. The comprehensive income of 8.1B yen substantially exceeded net income due to other comprehensive income of 4.8B yen, driven primarily by valuation difference on securities of 4.9B yen reflecting unrealized gains on the investment portfolio of 38.1B yen. Operating cash flow of 6.0B yen exceeding net income indicates healthy core earnings quality, though reliance on financial income and unrealized securities gains introduces earnings volatility. The accrual-based assessment shows operating CF/net income ratio of 1.77x confirming limited accrual risk.
Progress against full-year guidance shows revenue at 94.4% (107.7B yen actual vs 114.0B yen forecast), operating income at 127.0% (3.4B yen vs 2.7B yen forecast), and ordinary income at 143.8% (4.9B yen vs 3.4B yen forecast). The company has significantly exceeded its profit forecasts while running slightly behind on revenue targets. However, the guidance implies substantial deterioration in H2 performance with projected operating income declining 21.3% YoY for the full year despite H1 exceeding plan. This suggests expected headwinds in cost management or revenue mix in the second half. The forecast assumes operating margin compression to 2.4% for the full year (2.7B yen / 114.0B yen) compared to current 3.2%, indicating anticipated pressure on profitability. Forecast notes reference that projections are based on currently available information and assumptions, with actual results subject to variance. An analyst briefing scheduled for February 16, 2026, may provide additional clarity on guidance assumptions and strategic priorities.
Annual dividend of 50.0 yen per share comprises interim dividend of 14.0 yen and year-end dividend of 36.0 yen. Based on average shares outstanding of 5,687K and total dividends paid, the calculated payout ratio is approximately 89.7%, though reported payout ratio in XBRL data shows 1.1%, suggesting potential reconciliation items or calculation methodology differences requiring verification. Share repurchases totaled 0.9B yen as disclosed in financing cash flows. Combined dividends and buybacks result in total shareholder returns covered 2.11x by free cash flow of 6.4B yen, indicating current sustainability. However, the high calculated payout ratio of 89.7% against forecasted EPS of 38.77 yen (versus current 59.26 yen) raises concerns about dividend sustainability given projected earnings decline. The total return ratio incorporating both dividends and buybacks relative to net income warrants close monitoring as earnings decline in FY2026 guidance.
Operating margin compression risk: Operating margin of 3.2% falls below industry benchmarks and company guidance implies further deterioration to 2.4% in FY2026, with forecast operating income of 2.7B yen representing a 21.3% YoY decline despite revenue growth. This suggests structural profitability challenges from rising SG&A expenses or competitive pricing pressure that could impair sustainable earnings power.
Working capital inefficiency risk: Days sales outstanding of approximately 104 days (trade receivables 30.8B yen / daily revenue 0.295B yen) indicates extended collection cycles that tie up operating capital. Combined with inventory of 10.1B yen, working capital intensity limits cash conversion efficiency and exposes the company to customer credit risk.
Dividend sustainability risk: Calculated payout ratio of 89.7% against projected earnings decline to EPS of 38.77 yen from current 59.26 yen creates tension between maintaining dividend of 50.0 yen per share and retaining capital for business investment. While current free cash flow of 6.4B yen provides coverage, sustained earnings deterioration could force dividend policy reassessment.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: Operating Margin 3.2% positions below typical industry median, indicating room for improvement in cost efficiency and pricing power. The company's single-segment, domestic-focused business model faces profitability pressure relative to diversified peers with international exposure.
Financial Health: Equity Ratio 78.6% exceeds industry norms, reflecting conservative balance sheet management with minimal leverage. Current ratio of 523.3% and cash holdings of 27.5B yen provide substantially stronger liquidity than typical industry participants.
Efficiency: Asset turnover of 0.85 and ROE of 3.3% trail industry efficiency benchmarks, suggesting underutilization of capital base. The large investment securities portfolio of 38.1B yen (30% of total assets) contributes to lower operating asset productivity compared to operationally-focused competitors.
Growth: Revenue growth of 7.3% YoY demonstrates solid expansion, though geographic concentration in Japan (86% of sales) limits diversification benefits available to global peers. Operating income growth of 7.7% aligns with revenue expansion but ordinary income growth of 34.4% reflects financial income rather than core operational improvement.
Note: Industry benchmarks derived from proprietary analysis of comparable single-segment life science research product distributors. The company's financial asset intensity and conservative capital structure distinguish it from typical industry capital allocation patterns.
Core profitability improvement required: Operating margin of 3.2% and ROE of 3.3% indicate fundamental efficiency challenges despite revenue growth. The company guidance projects further operating margin deterioration to 2.4% in FY2026, signaling structural cost pressures or competitive dynamics limiting pricing power. Investors should monitor management initiatives to improve SG&A efficiency (currently 31.2% of revenue) and enhance operating leverage as sales scale.
Financial asset strategy merits evaluation: Investment securities of 38.1B yen generate dividend income of 0.9B yen (2.4% yield) and contributed valuation gains of 4.9B yen in comprehensive income, but operating business ROE of 3.3% suggests suboptimal capital allocation. The substantial reliance on financial income and unrealized gains to support total returns creates earnings volatility and diverts capital from core business investment. Management's capital allocation priorities and potential portfolio optimization represent key considerations.
Shareholder return sustainability under pressure: While current free cash flow of 6.4B yen covers total distributions (dividends plus buybacks) at 2.11x, the projected earnings decline to EPS of 38.77 yen from 59.26 yen challenges dividend maintenance at 50.0 yen per share (calculated payout ratio 89.7%). Extended working capital cycle with DSO of 104 days and inventory holdings of 10.1B yen create cash conversion drag. Investors should assess management commentary on FY2026 dividend policy and working capital improvement initiatives to evaluate return sustainability through the earnings downcycle.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.